Gilead NASH drug fails late stage trialGilead’s top late-stage drug selonsertib, for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), has failed a Share XGilead NASH drug fails late stage trialhttps://pharmaphorum.com/news/gilead-nash-drug-fails-late-stage-trial/
Pharma companies clear the R&D decks in Q4The fourth-quarter results season has already seen a host of unwanted projects cleared from pharma companies’ pipelines as Share XPharma companies clear the R&D decks in Q4https://pharmaphorum.com/news/pharma-companies-clear-the-rd-decks-in-q4/
Gilead hires Roche’s pharma chief Daniel O’Day as CEORoche executive Daniel O’Day is to take the helm at Gilead after John Milligan steps down as CEO Share XGilead hires Roche’s pharma chief Daniel O’Day as CEOhttps://pharmaphorum.com/news/gilead-hires-roches-pharma-chief-daniel-oday-as-ceo/
NICE gives final seal of approval for Gilead’s CAR-T in NHLNICE has finalised its guidance recommending interim NHS funding for Gilead’s Yescarta CAR-T therapy, to treat patients with Share XNICE gives final seal of approval for Gilead’s CAR-T in NHLhttps://pharmaphorum.com/news/nice-gives-final-seal-of-approval-for-gileads-car-t-in-nhl/
Gilead pushes on with NASH drug after phase 2 successGilead Sciences presented promising data on its research into advanced fibrosis caused by non-alcoholic steatohepatitis (NASH), one of Share XGilead pushes on with NASH drug after phase 2 successhttps://pharmaphorum.com/news/gilead-pushes-on-with-nash-drug-after-phase-2-success/
Novartis wants to blaze a trail in breast cancer with PI3K drugNovartis is preparing to file its PI3K drug combination for a certain group of breast cancer patients, after Share XNovartis wants to blaze a trail in breast cancer with PI3K drughttps://pharmaphorum.com/news/novartis-wants-to-blaze-a-trail-in-breast-cancer-with-pik3-drug/
NHS to reimburse Gilead’s CAR-T in adultsThe first CAR-T therapy aimed at adults with lymphoma is to be reimbursed in England after manufacturer Gilead Share XNHS to reimburse Gilead’s CAR-T in adultshttps://pharmaphorum.com/news/nhs-to-reimburse-gileads-car-t-in-adults/
Gilead signs biotech deal arming T-cells to attack solid tumoursGilead’s Kite unit has signed a deal with the biotech HiFiBiO (High Fidelity Biology) to discover T-cell receptors Share XGilead signs biotech deal arming T-cells to attack solid tumourshttps://pharmaphorum.com/news/gilead-signs-biotech-deal-arming-t-cells-to-attack-solid-tumours/
Gilead launches generics of own hepatitis C drugs in US to cut health costsGilead is to launch cheaper generic versions of its hepatitis C drugs in the US, responding to calls Share XGilead launches generics of own hepatitis C drugs in US to cut health costshttps://pharmaphorum.com/news/gilead-launches-generics-of-own-hepatitis-c-drugs-in-us-to-cut-health-costs/
